lerodalcibep PCSK9
Selected indexed studies
- PCSK9-directed therapies: an update. (Curr Opin Lipidol, 2024) [PMID:38277255]
- Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. (Lancet Diabetes Endocrinol, 2025) [PMID:39870096]
- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. (JAMA Cardiol, 2024) [PMID:38958989]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- PCSK9-directed therapies: an update. (2024) pubmed
- Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. (2025) pubmed
- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. (2024) pubmed
- The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. (2025) pubmed
- Lerodalcibep: First Approval. (2026) pubmed
- Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review. (2025) pubmed
- An up-to-date review of emerging biologic therapies for hypercholesterolemia. (2025) pubmed
- Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. (2026) pubmed
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. (2023) pubmed
- Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review. (2026) pubmed